Recent Finacing
Recent Raise
Cellestia Biotech is a clinical-stage biopharma developing CB-103, an oral small-molecule pan-NOTCH inhibitor for NOTCH-dependent leukemias, lymphomas and solid tumors, combining targeted drug development with patient-selection diagnostics.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
